Cargando...
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype. Programmed death ligand 1 (PD-L1) on immune cells (IC) using the VENTANA SP142 assay is linked to improved clinical outcome in atezolizumab plus nab—paclitaxel-treated patients with mTNBC in the IMpassion1...
Gardado en:
| Publicado en: | Appl Immunohistochem Mol Morphol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8132905/ https://ncbi.nlm.nih.gov/pubmed/33030848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000857 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|